NCT03901950

Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors

A Phrase I, Open-label, Multi-center, Non-randomized, Does Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: Evopoint Biosciences Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The research project is testing this potential new medication for advanced solid tumours. This research project is being done to get more information about the study drug (XNW7201). The study drug is a potential new medication that blocks the activity of a protein found in cancer cells called Wnt. Studies have shown that, in cancer, Wnt is involved in the uncontrolled growth of cancer cells and helping them survive. It is hoped that by blocking the activity of Wnt, the study drug may decrease the growth of cancer cells and their survival. The purpose of this research is to check that the study drug is safe and to see how well it is tolerated in participants with locally advanced or metastatic solid tumours. Another purpose is to find out the highest dose that is well tolerated (called the maximum tolerated dose) and the right dose to use in future clinical research studies with this potential new medication.

Conditions

• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	XNW7201 tablets	A wnt pathway inhibitor

Timeline

• Start date: 2019-07-01
• Primary completion: 2021-12-30
• Completion: 2022-06-30
• First posted: 2019-04-03
• Last updated: 2023-02-16

Locations

1 site across 1 country: Australia